RiboPGT-121-LS

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameRiboPGT-121-LS
Drug Alias NamemRNA-encoded broadly neutralizing antibody (BioNTech/Harvard Medical School)PGT-121-LS RibobNAbRiboPGT-121-LS
ClassificationCell and gene therapy > Gene therapy > LNPSmall molecules > Nucleosides and nucleotide derivtives > OligonucleotideBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionTransmembrane glycoprotein gp41 modulatorsHIV envelope protein gp120 modulators
TargetsHIV envelope protein gp120Transmembrane glycoprotein gp41
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHarvard Medical School
China Registration ClassN/A

Develop Information

Active CompaniesHarvard Medical SchoolBiontech Se
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A